NCT01891019View on ClinicalTrials.gov

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

June 30, 2009

Conditions
Psoriasis, Plaque-type
Interventions
DRUG

Thalidomide oral

Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.

Trial Locations (1)

27157

Wake Forest University Health Sciences Dermatology, Winston-Salem

All Listed Sponsors
lead

Wake Forest University

OTHER

NCT01891019 - Thalidomide in the Treatment of Chronic Plaque Psoriasis. | Biotech Hunter | Biotech Hunter